COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $15.8750.

CMPS has been the topic of a number of research reports. BTIG Research increased their price objective on shares of COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of COMPASS Pathways in a report on Wednesday, October 8th. Finally, Morgan Stanley raised their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th.

COMPASS Pathways Stock Performance

CMPS opened at $6.73 on Tuesday. COMPASS Pathways has a 1-year low of $2.25 and a 1-year high of $7.15. The stock has a market cap of $646.21 million, a P/E ratio of -2.47 and a beta of 1.93. The stock’s 50 day simple moving average is $5.98 and its 200 day simple moving average is $5.12. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. As a group, equities analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Hedge Funds Weigh In On COMPASS Pathways

Hedge funds have recently bought and sold shares of the stock. Advisory Services Network LLC purchased a new position in shares of COMPASS Pathways during the 3rd quarter worth about $41,000. China Universal Asset Management Co. Ltd. increased its position in COMPASS Pathways by 46.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock worth $51,000 after purchasing an additional 5,817 shares during the last quarter. BIT Capital GmbH purchased a new position in COMPASS Pathways during the third quarter worth approximately $54,000. Conservest Capital Advisors Inc. raised its stake in COMPASS Pathways by 32.5% during the second quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock worth $57,000 after purchasing an additional 5,000 shares during the period. Finally, Northeast Financial Consultants Inc acquired a new position in shares of COMPASS Pathways in the 2nd quarter valued at $59,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.